The results of a recent multicenter clinical trial showed that the use of evolocumab reduces the 30-day mortality rate or intubation requirement in severe COVID-19 patients by 30%, accompanied by a significant reduction in serum IL-6 levels (101, 107). Here, IL6 is linked to COVID-19.